Literature DB >> 23438276

Colorectal cancer with multiple metachronous metastasis achieving complete remission 14 years after surgical resection: report of a case.

Koji Murono1, Kazushige Kawai, Shinsuke Kazama, Nelson H Tsuno, Eiji Sunami, Joji Kitayama, Toshiaki Watanabe.   

Abstract

A 63-year-old man underwent a colectomy for sigmoid colon cancer in 1997. The upper lobe of his left lung and his left adrenal gland were resected because of metachronous metastases, 7 and 10 years after the initial surgery, respectively. Recurrence of metastases to the middle lobe of the right lung and left adrenal gland were sequentially detected in 2007, and a multimodal therapy, consisting of the combination of radiotherapy and chemotherapy, was conducted since 2007. The chemotherapy included drugs such as FOLFOX, FOLFIRI, bevacizumab, capecitabine, and cetuximab. In 2011, the complete response of all metastatic lesions could be achieved, and no recurrence was detected for more than 1 year. In spite of repeated recurrences, by the combination of surgical resection, chemotherapy, and radiotherapy, the complete response could be achieved 14 years after the initial surgical resection, which can be attributed to the development of new treatment modalities and new agents for colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23438276      PMCID: PMC3723164          DOI: 10.9738/CC172.1

Source DB:  PubMed          Journal:  Int Surg        ISSN: 0020-8868


  14 in total

1.  A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma.

Authors:  N Petrelli; L Herrera; Y Rustum; P Burke; P Creaven; J Stulc; L J Emrich; A Mittelman
Journal:  J Clin Oncol       Date:  1987-10       Impact factor: 44.544

2.  Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study.

Authors:  P M Hoff; R Ansari; G Batist; J Cox; W Kocha; M Kuperminc; J Maroun; D Walde; C Weaver; E Harrison; H U Burger; B Osterwalder; A O Wong; R Wong
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.

Authors:  J Y Douillard; D Cunningham; A D Roth; M Navarro; R D James; P Karasek; P Jandik; T Iveson; J Carmichael; M Alakl; G Gruia; L Awad; P Rougier
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

4.  Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.

Authors:  A de Gramont; J F Bosset; C Milan; P Rougier; O Bouché; P L Etienne; F Morvan; C Louvet; T Guillot; E François; L Bedenne
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  Durable complete responses in metastatic colorectal cancer treated with chemotherapy alone.

Authors:  Renata Ferrarotto; Priyanka Pathak; Dipen Maru; Atin Agarwal; Michael Overman; Paulo M Hoff; Scott Kopetz
Journal:  Clin Colorectal Cancer       Date:  2011-04-24       Impact factor: 4.481

Review 6.  Critical evaluation of current treatments in metastatic colorectal cancer.

Authors:  Alan Venook
Journal:  Oncologist       Date:  2005-04

7.  Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

Authors:  A de Gramont; A Figer; M Seymour; M Homerin; A Hmissi; J Cassidy; C Boni; H Cortes-Funes; A Cervantes; G Freyer; D Papamichael; N Le Bail; C Louvet; D Hendler; F de Braud; C Wilson; F Morvan; A Bonetti
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

8.  Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Authors:  Eric Van Cutsem; Marc Peeters; Salvatore Siena; Yves Humblet; Alain Hendlisz; Bart Neyns; Jean-Luc Canon; Jean-Luc Van Laethem; Joan Maurel; Gary Richardson; Michael Wolf; Rafael G Amado
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

9.  Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

Authors:  David Cunningham; Yves Humblet; Salvatore Siena; David Khayat; Harry Bleiberg; Armando Santoro; Danny Bets; Matthias Mueser; Andreas Harstrick; Chris Verslype; Ian Chau; Eric Van Cutsem
Journal:  N Engl J Med       Date:  2004-07-22       Impact factor: 91.245

10.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

View more
  1 in total

1.  Complete Response With Cetuximab-Based Treatment of Metastatic Colorectal Cancers: Two Case Reports and Literature Review.

Authors:  Li Wei; Zexiao Lin; Sidong Xie; Danyun Ruan; Wen Jiang; Yueli Cui; Sisi Liu; Tiantian Wang; Zhanhong Chen; Qu Lin
Journal:  Front Oncol       Date:  2022-02-16       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.